Peipei Ye, Yixuan Cheng, Jiaying Lian, Hongyan Tong, Linjie Li, Qunyi Guo, Weiguo Zhu, Weiying Feng, Li Huang, Lihong Shou, Dong Chen, Xuhui Liu, Shuangyue Li, Xiaohong Du, Min Yang, Wenjuan Yu, Jiejing Qian, Chao Hu, Huafeng Wang, Yangjin Jin, Jian Shen, Pan Hong, Renzhi Pei, Jie Jin, Ying Lu
A chemotherapy-based mobilization regimen in patients who mobilize poorly, based on etoposide, cytarabine and pegfilgrastim (EAP), has recently been introduced. The aim of this prospective study was to investigate the efficacy and safety of the EAP regimen in patients with poorly mobilizing multiple myeloma (MM) or lymphoma. This single-arm clinical trial was performed at eight public hospitals in China and was registered as a clinical trial (NCT05510089). The inclusion criteria were; (1) diagnosis of MM or lymphoma, (2) defined as a 'poor mobilizer' and (3) aged 18-75 years...
February 23, 2024: British Journal of Haematology